Blood sugar, liver enzymes, and kidney function are good to monitor over time
Given the huge unmet need and major health challenges, the negative trial results are very disappointing, and a sobering reminder that GLP-1 medicines will not be helpful for every medical condition, Daniel Drucker, an endocrinologist at the Lunenfeld-Tanenbaum Research Institute and a recent winner of the 2025 Breakthrough Prize in Life Sciences for his role in the development of GLP-1 agonists, told DDN
Tirzepatide, a dual GLP-1/GIP agonist marketed as Zepbound and Mounjaro, pushed that even further with up to 22.5% weight reduction
For people with diabetes who are also taking insulin or sulfonylureas, it's important to discuss with your healthcare provider whether nocturnal hypoglycaemia might be contributing to sleep disturbances
Tirzepatides dual GIP/GLP-1 mechanism has demonstrated superior weight-loss efficacy in both clinical trials and real-world studies, enabling stronger payer uptake and prescriber preference
